Literature DB >> 18684116

The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland.

S J Moore1, D J Buckley, A MacMillan, H D Marshall, L Steele, P N Ray, Z Nawaz, B Baskin, M Frecker, S M Carr, E Ives, P S Parfrey.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs) are the commonest neurodegenerative disorders of children. The aims of this study were to determine the incidence of NCL in Newfoundland, identify the causative genes, and analyze the relationship between phenotype and genotype. Patients with NCL diagnosed between 1960 and 2005 were ascertained through the provincial genetics and pediatric neurology clinics. Fifty-two patients from 34 families were identified. DNA was obtained from 28/34 (82%) families; 18 families had mutations in the CLN2 gene, comprising five different mutations of which two were novel. One family had a CLN3 mutation, another had a novel mutation in CLN5, and five families shared the same mutation in CLN6. One family was misdiagnosed, and in two, molecular testing was inconclusive. Disease from CLN2 mutations had an earlier presentation (p = 0.003) and seizure onset (p < 0.001) compared with CLN6 mutation. There was a slower clinical course for those with CLN5 mutation compared with CLN2 mutation. NCL in Newfoundland has a high incidence, 1 in 7353 live births, and shows extensive genetic heterogeneity. The incidence of late infantile NCL, 9.0 per 100,000 (or 1 in 11,161) live births, is the highest reported in the world.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684116     DOI: 10.1111/j.1399-0004.2008.01054.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  23 in total

1.  Genetic structure of the Newfoundland and Labrador population: founder effects modulate variability.

Authors:  Guangju Zhai; Jiayi Zhou; Michael O Woods; Jane S Green; Patrick Parfrey; Proton Rahman; Roger C Green
Journal:  Eur J Hum Genet       Date:  2015-12-16       Impact factor: 4.246

2.  Juvenile neuronal ceroid lipofuscinosis: clinical course and genetic studies in Spanish patients.

Authors:  María-Socorro Pérez-Poyato; Montserrat Milà Recansens; Isidre Ferrer Abizanda; Raquel Montero Sánchez; Laia Rodríguez-Revenga; Victoria Cusí Sánchez; M Mar García González; Rosario Domingo Jiménez; Rafael Camino León; Ramón Velázquez Fragua; Antonio Martínez-Bermejo; Mercè Pineda Marfà
Journal:  J Inherit Metab Dis       Date:  2011-04-16       Impact factor: 4.982

3.  Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  Erika F Augustine; Heather R Adams; Christopher A Beck; Amy Vierhile; Jennifer Kwon; Paul G Rothberg; Frederick Marshall; Robert Block; James Dolan; Jonathan W Mink
Journal:  Dev Med Child Neurol       Date:  2014-11-11       Impact factor: 5.449

4.  Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis.

Authors:  David E Sleat; Erika Gedvilaite; Yeting Zhang; Peter Lobel; Jinchuan Xing
Journal:  Gene       Date:  2016-08-20       Impact factor: 3.688

5.  Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6.

Authors:  Todor Arsov; Katherine R Smith; John Damiano; Silvana Franceschetti; Laura Canafoglia; Catherine J Bromhead; Eva Andermann; Danya F Vears; Patrick Cossette; Sulekha Rajagopalan; Alan McDougall; Vito Sofia; Michael Farrell; Umberto Aguglia; Andrea Zini; Stefano Meletti; Michela Morbin; Saul Mullen; Frederick Andermann; Sara E Mole; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2011-05-05       Impact factor: 11.025

6.  Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease.

Authors:  Kyle D Kovacs; Samir Patel; Anton Orlin; Keunpyo Kim; Sherri Van Everen; Therese Conner; Dolan Sondhi; Stephen M Kaminsky; Donald J D'Amico; Ronald G Crystal; Szilárd Kiss
Journal:  Ophthalmol Retina       Date:  2020-01-22

7.  Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.

Authors:  J Schaefers; L J van der Giessen; C Klees; E H Jacobs; S Sieverdink; M H G Dremmen; J K H Spoor; A T van der Ploeg; J M P van den Hout; H H Huidekoper
Journal:  Orphanet J Rare Dis       Date:  2021-05-14       Impact factor: 4.123

8.  Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).

Authors:  Paul Gissen; Nicola Specchio; Andrew Olaye; Mohit Jain; Thomas Butt; Wrik Ghosh; Benjamin Ruban-Fell; Annabel Griffiths; Charlotte Camp; Zlatko Sisic; Christoph Schwering; Eva Wibbeler; Marina Trivisano; Laura Lee; Miriam Nickel; Amanda Mortensen; Angela Schulz
Journal:  Orphanet J Rare Dis       Date:  2021-05-12       Impact factor: 4.123

Review 9.  A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis.

Authors:  I Basak; H E Wicky; K O McDonald; J B Xu; J E Palmer; H L Best; S Lefrancois; S Y Lee; L Schoderboeck; S M Hughes
Journal:  Cell Mol Life Sci       Date:  2021-04-01       Impact factor: 9.261

10.  Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy.

Authors:  Filippo Maria Santorelli; Barbara Garavaglia; Francesco Cardona; Nardo Nardocci; Bernardo Dalla Bernardina; Stefano Sartori; Agnese Suppiej; Enrico Bertini; Dianela Claps; Roberta Battini; Roberta Biancheri; Mirella Filocamo; Francesco Pezzini; Alessandro Simonati
Journal:  Orphanet J Rare Dis       Date:  2013-02-02       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.